Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPN021
MIFTS: 50

Spinal Meningioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Spinal Meningioma

About this section

MalaCards integrated aliases for Spinal Meningioma:

Name: Spinal Meningioma 12 54 15 74
Meningioma 45 74
Meningioma, Benign, No Icd-O Subtype 74
Spinal Cord Meningioma 12
Meningioma, Spine 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1138
MeSH 45 D008579
NCIt 51 C6935
Sources

Summaries for Spinal Meningioma

About this section
NIH Rare Diseases : 54 Spinal meningioma is a rare type of spinal cord cancer.  The spinal cord is part of the central nervous system. This tumor often affects middle-aged women. Tumors of the spinal cord can be either primary or arise from other primary tumors (metastatic), and are typically slow growing. The initial signs and symptoms include headache and recent onset of seizures. Other features are motor deficits, sensory deficits, pain, and sphincter dysfunction. The thoracic spine (middle back) is the most common site, followed by the cervical spine (neck). These tumors are rarely seen in the lumbar region (lower back). The only proven risk factor in the development of meningioma is exposure to ionizing radiation. Also, patients with neurofibromatosis type 2 are at increased risk of developing meningioma. Surgery is the treatment of choice and complete tumor removal is reached in the vast majority of patients. The prognosis after surgical resection is excellent. 

MalaCards based summary : Spinal Meningioma, also known as meningioma, is related to lymphoplasmacyte-rich meningioma and benign meningioma. An important gene associated with Spinal Meningioma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Gastric cancer and Glioblastoma Multiforme. The drugs Thrombin and Coagulants have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Sources

Related Diseases for Spinal Meningioma

About this section

Diseases related to Spinal Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 621)
# Related Disease Score Top Affiliating Genes
1 lymphoplasmacyte-rich meningioma 33.7 MIB1 PGR
2 benign meningioma 33.5 NF2 PGR SMARCE1
3 lung meningioma 33.5 ENO2 PGR
4 olfactory groove meningioma 33.4 CHGA NF2 PGR
5 clear cell meningioma 33.4 CHGA PGR SMARCE1
6 anterior cranial fossa meningioma 33.3 CHGA NF2 PGR
7 meningothelial meningioma 33.3 ENO2 NF2 SMARCE1
8 microcystic meningioma 33.2 CDH17 ENO2
9 benign ependymoma 30.2 ENO2 NF2
10 meningocele 30.2 HSF4 NF1
11 neurilemmoma 30.1 ENO2 NF1 NF2 SOX10
12 pilocytic astrocytoma 30.1 NF1 SOX10
13 carcinoid syndrome 29.8 CHGA ENO2
14 neurofibroma 29.8 NF1 NF2 SOX10
15 neurilemmoma of the fifth cranial nerve 29.7 NF1 NF2
16 optic nerve glioma 29.6 ENO2 MIB1 NF1
17 paraganglioma 29.6 CHGA ENO2 NF1
18 dermoid cyst 29.6 CHGA PGR
19 leiomyosarcoma 29.4 ENO2 IGF2 PGR
20 central neurocytoma 29.3 CHGA ENO2
21 meningioma, familial 29.2 ENO2 IGF2 NF1 NF2 PGR SMARCE1
22 spinal canal and spinal cord meningioma 28.8 CDH17 CHGA CYP4F22 ENO2 FAT2 GFER
23 optic nerve sheath meningioma 12.4
24 intraorbital meningioma 12.3
25 rhabdoid meningioma 12.2
26 childhood brain meningioma 12.2
27 meningioma, radiation-induced 12.2
28 brain meningioma 12.2
29 chordoid meningioma 12.1
30 fibrous meningioma 12.1
31 transitional meningioma 12.1
32 cerebral meningioma 12.1
33 tuberculum sellae meningioma 12.1
34 skull base meningioma 12.1
35 foramen magnum meningioma 12.1
36 cerebellopontine angle meningioma 12.1
37 cavernous sinus meningioma 12.1
38 angiomatous meningioma 12.1
39 cerebral falx meningioma 12.1
40 pineal region meningioma 12.1
41 psammomatous meningioma 12.1
42 petrous apex meningioma 12.1
43 parasagittal meningioma 12.1
44 intraventricular meningioma 12.1
45 middle cranial fossa meningioma 12.1
46 petroclival meningioma 12.1
47 choroid plexus meningioma 12.1
48 suprasellar meningioma 12.1
49 jugular foramen meningioma 12.1
50 internal auditory canal meningioma 12.1

Graphical network of the top 20 diseases related to Spinal Meningioma:



Diseases related to Spinal Meningioma
Sources

Symptoms & Phenotypes for Spinal Meningioma

About this section

MGI Mouse Phenotypes related to Spinal Meningioma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.76 CHGA IGF2 MIB1 NF1 NF2 PGR
2 growth/size/body region MP:0005378 9.61 CHGA ENO2 GFER IGF2 MIB1 NF1
3 limbs/digits/tail MP:0005371 9.1 IGF2 MIB1 NF1 PGR SOX10 TG
Sources

Drugs & Therapeutics for Spinal Meningioma

About this section

Drugs for Spinal Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 271)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2 Coagulants Phase 4,Phase 3
3 Hemostatics Phase 4,Phase 3
4 Fibrin Tissue Adhesive Phase 4
5
Tranexamic Acid Approved Phase 3 1197-18-8 5526
6
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
7
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
8
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
12
Cisplatin Approved Phase 3,Phase 2 15663-27-1 441203 84093 2767
13
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
16
Cisatracurium Approved Phase 3 96946-41-7
17
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
18
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
19
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
20
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
21
Cyproheptadine Approved Phase 3 129-03-3 2913
22
Histamine Approved, Investigational Phase 3 51-45-6 774
23
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1 7440-70-2 271
24 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
25 Antifibrinolytic Agents Phase 3
26 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Dermatologic Agents Phase 3,Phase 2,Phase 1
28 Contraceptive Agents Phase 3
29 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
30 Contraceptives, Oral Phase 3
31 Contraceptives, Postcoital Phase 3
32 Progestins Phase 3
33 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
34 Luteolytic Agents Phase 3
35 glucocorticoids Phase 3,Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
37 Nootropic Agents Phase 3,Phase 2,Early Phase 1
38 Cholinesterase Inhibitors Phase 3,Phase 2,Early Phase 1
39 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Early Phase 1
40 Cholinergic Agents Phase 3,Phase 2,Early Phase 1
41 Anesthetics Phase 3,Not Applicable
42 Anesthetics, Intravenous Phase 3
43 Narcotics Phase 3
44 Cola Phase 3,Phase 1
45 Analgesics, Opioid Phase 3
46 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Analgesics Phase 3,Phase 2,Phase 1
49 Liver Extracts Phase 3,Phase 1,Phase 2
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Cavernous Sinus Dissection and Bleeding in Meningiomas Unknown status NCT02863484 Phase 4
2 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
3 Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Not yet recruiting NCT03190122 Phase 4
4 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
5 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
6 S9005 Mifepristone in Meningioma Completed NCT03015701 Phase 3 Mifepristone
7 Proton/Photon Rt - Benign Meningiomas(P92-13) Completed NCT02947984 Phase 3
8 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
11 Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery Recruiting NCT03180268 Phase 3
12 Magnesium and Intraoperative Blood Loss in Meningioma Surgery Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
13 Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery Terminated NCT00104936 Phase 3
14 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
17 Proton Radiation For Meningiomas and Hemangiopericytomas Unknown status NCT01117844 Phase 1, Phase 2
18 Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
19 Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
20 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
21 Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
22 Trabectedin for Recurrent Grade II/III Meningioma Completed NCT02234050 Phase 2 Trabectedin
23 S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma Completed NCT00003590 Phase 2 hydroxyurea
24 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
25 Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
26 Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma Completed NCT00626730 Phase 2
27 Imatinib Mesylate in Treating Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
28 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
29 Vatalanib in Treating Patients With Recurrent or Progressive Meningioma Completed NCT00348790 Phase 2 vatalanib
30 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
31 Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
32 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
33 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
34 Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Completed NCT00025675 Phase 2 gefitinib
35 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
36 Theranostics: 68GaDOTATOC and 90YDOTATOC Completed NCT02441088 Phase 2 90Y-DOTA-tyr3-Octreotide;Aminosyn II
37 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
38 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
39 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
40 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
41 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
42 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
43 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
44 SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy Completed NCT00004868 Phase 1, Phase 2 semaxanib
45 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
46 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
47 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
48 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
49 Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Recruiting NCT03071874 Phase 2 AZD2014
50 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab

Search NIH Clinical Center for Spinal Meningioma

Cochrane evidence based reviews: meningioma

Sources

Genetic Tests for Spinal Meningioma

About this section
Sources

Anatomical Context for Spinal Meningioma

About this section

MalaCards organs/tissues related to Spinal Meningioma:

42
Brain, Spinal Cord, Bone, T Cells, Endothelial, Pituitary, Thyroid
Sources

Publications for Spinal Meningioma

About this section

Articles related to Spinal Meningioma:

(show top 50) (show all 1813)
# Title Authors Year
1
Whole-tumor histogram analysis of apparent diffusion coefficient in differentiating intracranial solitary fibrous tumor/hemangiopericytoma from angiomatous meningioma. ( 30777209 )
2019
2
Meningioma Screening with MRI in Childhood Leukemia Survivors Treated with Cranial Radiation. ( 30880270 )
2019
3
Large falcine meningioma presented as treatment-resistant depression: A case report. ( 30846670 )
2019
4
Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma ( 30909681 )
2019
5
Cluster-Like Headache Secondary to Anamnesis of Sphenoid Ridge Meningioma: A Case Report and Literature Review. ( 30740086 )
2019
6
Intraventricular Meningioma Presenting As Lateral Posterior Choroidal Artery Stroke. ( 30822588 )
2019
7
Editors' note: Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. ( 30833477 )
2019
8
Reader response: Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. ( 30833478 )
2019
9
Author response: Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. ( 30833479 )
2019
10
Visual Outcomes of Fractionated Radiotherapy in Optic Nerve Sheath Meningioma: A Retrospective Study. ( 30812038 )
2019
11
Non secretory Paraganglioma in cavernous sinus masquerading as meningioma. ( 30831293 )
2019
12
Petroclival Meningioma Presenting With an Ipsilateral Sixth Nerve Palsy and a Contralateral Homonymous Quadrantanopia: A Unique and Topographically Localizing Syndrome. ( 30664101 )
2019
13
A comprehensive study of risk factors for post-operative pneumonia following resection of meningioma. ( 30674295 )
2019
14
New-onset psychiatric symptoms following intracranial meningioma in a patient with schizophrenia: a case study. ( 30758462 )
2019
15
Placement of cesium-131 permanent brachytherapy seeds using the endoscopic endonasal approach for recurrent anaplastic skull base meningioma: case report and technical note. ( 30835687 )
2019
16
EQ-5D Quality-of-Life Analysis and Cost-Effectiveness After Skull Base Meningioma Resection. ( 30869135 )
2019
17
Spontaneous Hemorrhage followed by paraparesis in a patient with a Spinal Meningioma. ( 30684702 )
2019
18
Magnetic resonance imaging spectrum of spinal meningioma. ( 30802771 )
2019
19
Proposed Treatment for Intracranial Transitional Meningioma: a single-center series of 298 cases. ( 30902770 )
2019
20
Uptake and Tracer Kinetic of O-(2-(18)F-fluoroethyl)-L-Tyrosine in Meningioma. ( 30540599 )
2019
21
Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. ( 30546952 )
2019
22
Whole-Body Staging of Metastatic Atypical Meningioma Using 68Ga-DOTATATE PET/CT. ( 30589668 )
2019
23
Meningioma grading using conventional MRI histogram analysis based on 3D tumor measurement. ( 30599872 )
2019
24
5-aminolevulinic acid induced protoporphyrin IX (ALA-PpIX) fluorescence guidance in meningioma surgery. ( 30604395 )
2019
25
Malignant meningioma mimicking chronic subdural hematoma. ( 30611944 )
2019
26
Treatment Strategy for Recurrent Hemorrhage from Meningioma: Case Report and Literature Review. ( 30620893 )
2019
27
Intrapulmonary metastasis from primary pulmonary meningioma presenting as multiple cystic lesions: a case report. ( 30621651 )
2019
28
A primary meningioma of the lumbar spine with neck metastasis. ( 30624157 )
2019
29
Infectious complications after surgery for a frontal meningioma. ( 30635323 )
2019
30
Contralateral facial nerve paresis subsequent to posterior fossa meningioma surgery in a child: case report. ( 30643949 )
2019
31
Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. ( 30649488 )
2019
32
PARATHYROID SESTAMIBI REVEALS MENINGIOMA. ( 30657364 )
2019
33
Apparent diffusion coefficient values in differential diagnosis and prognostic prediction of solitary of fibrous tumor/hemangiopericytoma (WHOII) and atypical meningioma. ( 30664513 )
2019
34
Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. ( 30666456 )
2019
35
The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival. ( 30519894 )
2019
36
Risk Factors and Associated Complications of Symptomatic Venous Thromboembolism in Patients with Craniotomy for Meningioma. ( 30468929 )
2019
37
Atypical Intracranial Meningioma with Metastasis to C7 Vertebral Body: A Case Report. ( 30465962 )
2019
38
In vitro assessment of radiobiology of meningioma: A pilot study. ( 30408557 )
2019
39
Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy. ( 30392090 )
2019
40
Giant posterior fossa meningioma: the importance of early diagnosis and challenges concerning treatment. ( 30898941 )
2019
41
Acute Vision Loss After Ophthalmic Artery Embolization of Meningioma. ( 30893270 )
2019
42
Endoscopic Endonasal Transpituitary Gland Approach for Resection of Dorsum Sellae Meningioma - Technical Case Report. ( 30888025 )
2019
43
Can amide proton transfer-weighted imaging differentiate tumor grade and predict Ki-67 proliferation status of meningioma? ( 30887206 )
2019
44
Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort. ( 30615143 )
2019
45
Mendelian randomization provides support for obesity as a risk factor for meningioma. ( 30670737 )
2019
46
Neurosurgical treatment and outcome patterns of meningioma in Sweden: a nationwide registry-based study. ( 30675656 )
2019
47
Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. ( 30680963 )
2019
48
A rare case of sclerosing meningioma with immunohistochemical features. ( 30681002 )
2019
49
Differentiation between intraspinal schwannoma and meningioma by MR characteristics and clinic features. ( 30684254 )
2019
50
Meningioma surgery - Are we making progress? ( 30684722 )
2019
Sources

Variations for Spinal Meningioma

About this section
Sources

Expression for Spinal Meningioma

About this section
Search GEO for disease gene expression data for Spinal Meningioma.
Sources

Pathways for Spinal Meningioma

About this section

Pathways related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Gastric cancer 38
Show member pathways
 11.92 CDH17 IGF2 PGR SMARCE1
2
Glioblastoma Multiforme 65
10.84 IGF2 NF1 NF2
Sources

GO Terms for Spinal Meningioma

About this section

Biological processes related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peripheral nervous system development GO:0007422 9.16 NF1 SOX10
2 negative regulation of MAPK cascade GO:0043409 8.96 NF1 NF2
3 negative regulation of cell-matrix adhesion GO:0001953 8.62 NF1 NF2

Molecular functions related to Spinal Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 8.92 HSF4 PGR SMARCE1 SOX10
Sources

Sources for Spinal Meningioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....